Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
IPO Year: 2021
Exchange: NASDAQ
Website: ikenaoncology.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/29/2024 | $8.00 → $2.00 | Outperform → Neutral | Wedbush |
| 9/22/2023 | $11.00 | Outperform | Wedbush |
| 5/4/2023 | $18.00 | Buy | H.C. Wainwright |
| 12/23/2021 | $25.00 | Buy | HC Wainwright & Co. |
| 8/13/2021 | $30.00 → $27.00 | Outperform | Credit Suisse |
SCHEDULE 13D/A - Ikena Oncology, Inc. (0001835579) (Subject)
SCHEDULE 13D - Ikena Oncology, Inc. (0001835579) (Subject)
EFFECT - Ikena Oncology, Inc. (0001835579) (Filer)
424B3 - Ikena Oncology, Inc. (0001835579) (Filer)
S-4/A - Ikena Oncology, Inc. (0001835579) (Filer)
S-4/A - Ikena Oncology, Inc. (0001835579) (Filer)
S-4/A - Ikena Oncology, Inc. (0001835579) (Filer)
10-Q - Ikena Oncology, Inc. (0001835579) (Filer)
S-4/A - Ikena Oncology, Inc. (0001835579) (Filer)
S-4/A - Ikena Oncology, Inc. (0001835579) (Filer)
4 - Ikena Oncology, Inc. (0001835579) (Issuer)
4 - Ikena Oncology, Inc. (0001835579) (Issuer)
4 - Ikena Oncology, Inc. (0001835579) (Issuer)
4 - Ikena Oncology, Inc. (0001835579) (Issuer)
4 - Ikena Oncology, Inc. (0001835579) (Issuer)
4 - Ikena Oncology, Inc. (0001835579) (Issuer)
4 - Ikena Oncology, Inc. (0001835579) (Issuer)
4 - Ikena Oncology, Inc. (0001835579) (Issuer)
3 - Ikena Oncology, Inc. (0001835579) (Issuer)
4 - Ikena Oncology, Inc. (0001835579) (Issuer)
Wedbush downgraded Ikena Oncology from Outperform to Neutral and set a new price target of $2.00 from $8.00 previously
Wedbush initiated coverage of Ikena Oncology with a rating of Outperform and set a new price target of $11.00
H.C. Wainwright resumed coverage of Ikena Oncology with a rating of Buy and set a new price target of $18.00
HC Wainwright & Co. initiated coverage of Ikena Oncology with a rating of Buy and set a new price target of $25.00
Credit Suisse reiterated coverage of Ikena Oncology with a rating of Outperform and set a new price target of $27.00 from $30.00 previously
Credit Suisse resumed coverage of Ikena Oncology with a rating of Outperform and set a new price target of $30.00
Credit Suisse resumed coverage of Ikena Oncology with a rating of Outperform and set a new price target of $30.00
William Blair initiated coverage of Ikena Oncology with a rating of Outperform
Jefferies initiated coverage of Ikena Oncology with a rating of Buy
Credit Suisse initiated coverage of Ikena Oncology with a rating of Outperform and set a new price target of $30.00